Establishing the CQAs of a mAb product by evaluating impact and uncertainty during risk assessment.
Andrew Weiskopf
Advertisement
Andrew Weiskopf is director, technical development, Biogen Idec
Articles by Andrew Weiskopf
Advertisement
Latest Updated Articles
Defining Critical Quality Attributes for Monoclonal Antibody Therapeutic ProductsPublished: July 1st 2014 | Updated:
Advertisement
Advertisement
